keyword
https://read.qxmd.com/read/25420813/diabetes-mellitus-and-renal-transplantation-in-adults-is-there-enough-evidence-for-diagnosis-treatment-and-prevention-of-new-onset-diabetes-after-renal-transplantation
#21
REVIEW
O Suarez, M Pardo, S Gonzalez, D P Escobar-Serna, D A Castaneda, D Rodriguez, J C Osorio, E Lozano
BACKGROUND: New-onset diabetes after renal transplantation (NODAT) is one of the most frequent metabolic complications after transplantation; it is present in ∼25% of kidney transplant recipients, increasing their cardiovascular risk and inducing graft damage. The medical approach of this entity is still a matter of controversy, so our aim was to review the evidence available and offer a practical approach for diagnosis, treatment, and follow-up. METHODS: A systematic review of the literature in the Medline, Embase, Cochrane, and Lilacs databases was carried out with the use of the terms "Diabetes Mellitus," "Kidney Transplantation," "Drug Therapy," "Prognosis," "Therapeutics," and "Risk Factors...
November 2014: Transplantation Proceedings
https://read.qxmd.com/read/25416857/belatacept-for-kidney-transplant-recipients
#22
REVIEW
Philip Masson, Lorna Henderson, Jeremy R Chapman, Jonathan C Craig, Angela C Webster
BACKGROUND: Most people who receive a kidney transplant die from either cardiovascular disease or cancer before their transplant fails. The most common reason for someone with a kidney transplant to lose the function of their transplanted kidney necessitating return to dialysis is chronic kidney transplant scarring. Immunosuppressant drugs have side effects that increase risks of cardiovascular disease, cancer and chronic kidney transplant scarring. Belatacept may provide sufficient immunosuppression while avoiding unwanted side effects of other immunosuppressant drugs...
November 24, 2014: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/24275847/safety-of-immunosuppressive-drugs-used-as-maintenance-therapy-in-kidney-transplantation-a-systematic-review-and-meta-analysis
#23
JOURNAL ARTICLE
Celline Cardoso Almeida, Micheline Rosa Silveira, Vânia Eloisa de Araújo, Livia Lovato Pires de Lemos, Juliana de Oliveira Costa, Carlos Augusto Lins Reis, Francisco de Assis Acurcio, Maria das Gracas Braga Ceccato
To evaluate the safety of regimens containing calcineurin inhibitors (CNI), proliferation signal inhibitors (TOR-I) and antimetabolites, we conducted a meta-analysis of randomized clinical trials (RCTs) and observational studies. A total of 4,960 citations were identified in our electronic search and 14 additional articles were identified through hand searching. Forty-eight articles (11,432 participants) from 42 studies (38 RCTs and four cohorts) met the inclusion criteria. Meta-analysis results revealed the following: (i) tacrolimus was associated with an increased risk for diabetes and lower risk of dyslipidemia, compared to cyclosporine; (ii) mycophenolate mofetil (MMF) was associated with increased risk for total infections, abdominal pain, diarrhea and vomiting, compared with azathioprine; (iii) sirolimus was associated with higher risk of anemia, diabetes, dyslipidemia, lymphoceles and withdrawal compared to tacrolimus or cyclosporine, and cyclosporine was associated with an increased risk of CMV infection; (iv) the combination of CNI with antimetabolites was associated with more adverse events than CNI alone; (v) TOR-I was related to more adverse events than MMF...
2013: Pharmaceuticals
https://read.qxmd.com/read/23921809/sirolimus-versus-tacrolimus-in-kidney-transplant-recipients-receiving-mycophenolate-mofetil-and-steroids-focus-on-acute-rejection-patient-and-graft-survival
#24
COMPARATIVE STUDY
Aifang Yang, Bin Wang
The study aims to conduct a meta-analysis of randomized controlled trials to compare the efficacy of tacrolimus (TAC)/mycophenolate mofetil (MMF)/corticosteroids (CSs) with sirolimus (SRL)/MMF/CSs in renal transplant recipients: Research 2 databases, PubMed, and Web of Science, selecting relevant articles. Data were selected for acute rejection and patient and graft survival. Statistical value relative risk (RR) and 95% confidence intervals (CIs) were recorded. Six randomized controlled trials involving 885 patients were included...
March 2015: American Journal of Therapeutics
https://read.qxmd.com/read/20464732/drug-eluting-stents-versus-bare-metal-stents-for-angina-or-acute-coronary-syndromes
#25
REVIEW
Janette Greenhalgh, Juliet Hockenhull, Naveen Rao, Yenal Dundar, Rumona C Dickson, Adrian Bagust
BACKGROUND: Coronary artery stents are tiny tubular devices used to 'scaffold' vessels open during percutaneous transluminal coronary angioplasty (PTCA). Restenosis (re-narrowing) of vessels treated with stents is a problem; in order to reduce restenosis, stents that elute drugs over time are now available. However these drug-eluting stents are more expensive and there is a need to assess their clinical benefits prior to recommending their use. OBJECTIVES: To examine evidence from randomised controlled trials (RCTs) to assess the impact of drug eluting stents (DES) compared to bare metal stents (BMS) in the reduction of cardiac events...
2010: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/19517754/-monitoring-and-adjustment-of-immunosuppression-after-heart-transplantation
#26
REVIEW
P Yerly, F Mach, A Kalangos, S Rotman, L von Segesser, P Vogt, R Hullin, M Pascual
Heart transplantation remains the best therapeutic option for the treatment of end-stage heart failure. However, good survival rates can be obtained only if patients are closely monitored, particularly for their immunosuppressive regimens. Currently, a triple-drug regimen usually based on calcineurin-inhibitors (cyclosporin A or tacrolimus), anti-proliferative agents and steroids is used in most recipients. New agents such as the mTOR inhibitors, a more recently developed class of immunosuppressive drugs, can also be used in some patients...
May 27, 2009: Revue Médicale Suisse
https://read.qxmd.com/read/18385422/sirolimus-is-associated-with-new-onset-diabetes-in-kidney-transplant-recipients
#27
JOURNAL ARTICLE
Olwyn Johnston, Caren L Rose, Angela C Webster, John S Gill
New-onset diabetes (NOD) is associated with transplant failure. A few single-center studies have suggested that sirolimus is associated with NOD, but this is not well established. With the use of data from the United States Renal Data System, this study evaluated the association between sirolimus use at the time of transplantation and NOD among 20,124 adult recipients of a first kidney transplant without diabetes. Compared with patients treated with cyclosporine and either mycophenolate mofetil orazathioprine, sirolimus-treated patients were at increased risk for NOD, whether it was used in combination with cyclosporine (adjusted hazard ratio [HR] 1...
July 2008: Journal of the American Society of Nephrology: JASN
https://read.qxmd.com/read/17289741/clinical-impact-of-in-stent-late-loss-after-drug-eluting-coronary-stent-implantation
#28
JOURNAL ARTICLE
Raúl Moreno, Cristina Fernandez, Angel Sanchez-Recalde, Guillermo Galeote, Luis Calvo, Fernando Alfonso, Rosana Hernandez, Rosa Sánchez-Aquino, Dominick J Angiolillo, Sergio Villarreal, Carlos Macaya, Jose L Lopez-Sendon
AIMS: Controversy exists about the clinical significance of in-stent late loss (ISLL) after drug-eluting stent (DES) implantation. We sought to clarify whether ISLL after DES implantation is related to a potential clinical impact. METHODS AND RESULTS: We included in a meta-regression analysis 21 trials (8641 patients) that randomly compared DES with bare-metal stents (BMS). We evaluated the relationship between angiographic behaviour of DES and the clinical impact of using DES instead of BMS in each trial using meta-regression techniques, weighting by the number of patients included in each trial...
July 2007: European Heart Journal
https://read.qxmd.com/read/17134597/a-systematic-review-and-economic-model-of-the-clinical-and-cost-effectiveness-of-immunosuppressive-therapy-for-renal-transplantation-in-children
#29
REVIEW
G Yao, E Albon, Y Adi, D Milford, S Bayliss, A Ready, J Raftery, R S Taylor
OBJECTIVES: To review the clinical and cost-effectiveness of basiliximab, daclizumab, tacrolimus, mycophenolate mofetil (MMF), mycophenolate sodium (MPS) and sirolimus as possible immunosuppressive therapies for renal transplantation in children. DATA SOURCES: Electronic databases were searched up to November 2004. REVIEW METHODS: Data from selected studies were extracted and quality assessed. An economic model [Birmingham Sensitivity Analysis paediatrics (BSAp)] was produced based on an adaptation of a model previously developed for the assessment of the cost-effectiveness of immunosuppressants in adults following renal transplant...
December 2006: Health Technology Assessment: HTA
https://read.qxmd.com/read/15899149/clinical-and-cost-effectiveness-of-newer-immunosuppressive-regimens-in-renal-transplantation-a-systematic-review-and-modelling-study
#30
REVIEW
R Woodroffe, G L Yao, C Meads, S Bayliss, A Ready, J Raftery, R S Taylor
OBJECTIVES: To examine the clinical effectiveness and cost-effectiveness of the newer immunosuppressive drugs for renal transplantation: basiliximab, daclizumab, tacrolimus, mycophenolate (mofetil and sodium) and sirolimus. DATA SOURCES: Electronic databases. Industry submissions. Current Clinical Trials register. Cochrane Collaboration Renal Disease Group. REVIEW METHODS: The review followed the InterTASC standards. Each of the five company submissions to the National Institute for Clinical Excellence (NICE) contained cost-effectiveness models, which were evaluated by using a critique covering (1) model checking, (2) a detailed model description and (3) model rerunning...
May 2005: Health Technology Assessment: HTA
https://read.qxmd.com/read/14720075/asthma-refractory-to-glucocorticoids-the-role-of-newer-immunosuppressants
#31
REVIEW
Chris J Corrigan
Asthma is orchestrated by cytokine products of activated T cells. Glucocorticoids are thought to ameliorate asthma at least partly through T cell inhibition. Consequently, other T cell immunomodulatory agents have been assessed for asthma therapy. Since these agents may have serious unwanted effects, attention has been focused on patients with severe asthma refractory to maximal topical, and additional systemic glucocorticoid therapy. Although gold salts show a modest but significant glucocorticoid-sparing effect in severe asthma, lung function is not improved and not all patients respond...
2002: American Journal of Respiratory Medicine: Drugs, Devices, and Other Interventions
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.